Thanks to the increased use of approved therapies.
According to a report by Delveinsight, the peanut allergy market in seven major markets (7mm) that are expected to expand at a CAGR of 16% in 2024.
The industry’s growth is attributed to increased use of approved therapies, expected entry of emerging therapies, and a slight increase in diagnosis.
“Palforzia orally administered Palforzia provides a convenient and accessible treatment regimen compared to traditional SC, intradermal and epidermal therapies,” the report said.
However, slow intake in Palfozia, inadequate diagnosis in mild patients and lack of recognized treatment options in adults may challenge market growth.
7mm = US, Germany, France, Italy, Spain, UK and Japan.
